Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyClinical Use of Measurable Residual Disease in CLL

Talking about the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel medications is Dr. Alexey V. Danilov, Professor and Co-Director of the Toni Stephenson Lymphoma Center at the City of Hope National Medical Center in Duarte, California.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form